Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTOPHER TSUNG LUNG HO

Allopathic & Osteopathic Physicians Dermatology

NPI
1679507537
CMS profile
303166
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$77,774.96

206 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 5; records 1–50 of 206 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTOPHER TSUNG LUNG HO

NPI 1679507537 · CMS profile ID 303166

Allopathic & Osteopathic Physicians / Dermatology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 5; records 1–50 of 206 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679507537?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTOPHER TSUNG LUNG HO, NPI 1679507537, CMS profile ID 303166. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 5; records 1–50 of 206 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679507537?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). CHRISTOPHER TSUNG LUNG HO, NPI 1679507537, CMS profile ID 303166. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 5; records 1–50 of 206 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679507537?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
CHRISTOPHER TSUNG LUNG HO, NPI 1679507537, CMS profile ID 303166, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 5; records 1–50 of 206 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1679507537?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

206 matching records · $77,774.96 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 206 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 206.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $18.5212/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721876367 CMS
Amgen Inc. $34.2012/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741376899 CMS
AbbVie Inc. $25.5512/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721876363 CMS
Amgen Inc. $1,750.0012/17/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741376911 CMS
Amgen Inc. $1,750.0012/16/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741376909 CMS
AbbVie Inc. $1,350.0012/15/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721876359 CMS
LEO Pharma Inc. $15.3812/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746677617 CMS
AbbVie Inc. $20.0412/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721876357 CMS
AbbVie Inc. $18.2812/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721876353 CMS
AbbVie Inc. $12.3312/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721876349 CMS
Amgen Inc. $13.2112/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741376897 CMS
Janssen Biotech, Inc. $99.9912/10/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719084049 CMS
Amgen Inc. $1,750.0012/09/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741376905 CMS
Janssen Biotech, Inc. $1.0612/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719084045 CMS
Janssen Biotech, Inc. $5.3112/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719084047 CMS
PFIZER INC. $9.4212/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743573789 CMS
Amgen Inc. $16.2012/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740969411 CMS
Lilly USA, LLC $22.3412/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728395307 CMS
Amgen Inc. $500.0012/03/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741376907 CMS
Sun Pharmaceutical Industries Inc. $19.6512/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728257061 CMS
AbbVie Inc. $8.7312/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721876345 CMS
Novartis Pharmaceuticals Corporation $960.0011/30/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725795061 CMS
AbbVie Inc. $1,350.0011/24/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721876341 CMS
AbbVie Inc. $1,350.0011/23/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721876339 CMS
AbbVie Inc. $23.7511/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721876335 CMS
Amgen Inc. $12.1011/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741376895 CMS
DERMIRA, INC. $20.5911/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736899455 CMS
Novartis Pharmaceuticals Corporation $6.8311/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725795107 CMS
AbbVie Inc. $7.9011/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721876327 CMS
AbbVie Inc. $25.5511/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721876331 CMS
Amgen Inc. $27.1211/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741376893 CMS
Amgen Inc. $1,750.0011/05/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741376903 CMS
Janssen Biotech, Inc. $8.4811/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719084043 CMS
GENZYME CORPORATION $20.3911/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744116585 CMS
Novartis Pharmaceuticals Corporation $24.9311/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725795103 CMS
Amgen Inc. $10.1710/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740969407 CMS
Novartis Pharmaceuticals Corporation $2.8810/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725795066 CMS
AbbVie Inc. $18.3810/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721876325 CMS
Galderma Laboratories, L.P. $19.5810/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726852399 CMS
AbbVie Inc. $18.9910/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721876321 CMS
AbbVie Inc. $20.1510/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721876319 CMS
Galderma Laboratories, L.P. $15.1110/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726852395 CMS
AbbVie Inc. $1,350.0010/19/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721876315 CMS
AbbVie Inc. $24.5110/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721876311 CMS
PFIZER INC. $13.3010/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743508653 CMS
AbbVie Inc. $1,350.0010/13/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721876307 CMS
Novartis Pharmaceuticals Corporation $24.4210/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725795099 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $20.2810/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737464229 CMS
Amgen Inc. $10.7610/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740969405 CMS
AbbVie Inc. $1,350.0010/06/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721876295 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $205,908.65 343
PY2020 $77,774.96 206
PY2021 $133,527.00 260
PY2022 $134,738.68 292
PY2023 $101,983.69 134
PY2024 $54,522.15 69
PY2025 $22,056.16 20

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2022 Principal investigator $105,671.24 11
PY2021 Principal investigator $144,092.68 4
PY2020 Principal investigator $655,216.54 25
PY2019 Principal investigator $403,059.40 25

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

25 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Sun Pharmaceutical Industries Inc. $982.80 12/14/2020 Non-covered Recipient Entity
LA UNIVERSAL RESEARCH CENTER INC
A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp No dispute reported 06/30/2026 726713213
Principal investigator 1 Bausch Health US, LLC $3,500.00 12/10/2020 Non-covered Recipient Individual A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2 ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-120 GEL AND IDP-120 VEHICLE GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737375443
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $3,000.00 10/03/2020 Non-covered Recipient Entity
LA UNIVERSAL RESEARCH CENTER INC
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 724610811
Principal investigator 1 Sun Pharmaceutical Industries Inc. $982.80 10/01/2020 Non-covered Recipient Entity
LA UNIVERSAL RESEARCH CENTER INC
A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp No dispute reported 06/30/2026 726713219
Principal investigator 1 Sun Pharmaceutical Industries Inc. $4,506.30 09/25/2020 Non-covered Recipient Entity
LA UNIVERSAL RESEARCH CENTER INC
A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp No dispute reported 06/30/2026 726713225
Principal investigator 1 Sun Pharmaceutical Industries Inc. $4,506.30 09/09/2020 Non-covered Recipient Entity
LA UNIVERSAL RESEARCH CENTER INC
A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp No dispute reported 06/30/2026 726713227
Principal investigator 1 Sun Pharmaceutical Industries Inc. $4,600.80 07/09/2020 Non-covered Recipient Entity
LA UNIVERSAL RESEARCH CENTER INC
A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp No dispute reported 06/30/2026 726713231
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $86,019.60 07/06/2020 Non-covered Recipient Entity
La Universal Research Center
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 736760513
Principal investigator 1 TARO PHARMACEUTICALS USA, INC. $9,152.00 06/20/2020 Non-covered Recipient Entity
L.A. Universal Research Center, Inc.
A Randomized, Double-Blind, Multiple Center Placebo Controlled Study Comparing Taro Product to RLD and Both Treatments to a Placebo Control in the Treatment of Acne Vulgaris No dispute reported 06/30/2026 721485553
Principal investigator 1 Sun Pharmaceutical Industries Inc. $6,773.40 06/04/2020 Non-covered Recipient Entity
LA UNIVERSAL RESEARCH CENTER INC
A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp No dispute reported 06/30/2026 726713235
Principal investigator 1 Sun Pharmaceutical Industries Inc. $2,376.00 06/04/2020 Non-covered Recipient Entity
LA UNIVERSAL RESEARCH CENTER INC
A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp No dispute reported 06/30/2026 726713239
Principal investigator 1 TARO PHARMACEUTICALS USA, INC. $3,000.00 05/07/2020 Non-covered Recipient Entity
L.A. Universal Research Center, Inc.
A Randomized, Double-Blind, Multiple Center Placebo Controlled Study Comparing Taro Product to RLD and Both Treatments to a Placebo Control in the Treatment of Acne Vulgaris No dispute reported 06/30/2026 721485511
Principal investigator 1 Bausch Health US, LLC $13,254.00 04/23/2020 Non-covered Recipient Individual A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2 ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-120 GEL AND IDP-120 VEHICLE GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737373975
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,000.00 04/01/2020 Non-covered Recipient Entity
LA UNIVERSAL RESEARCH CENTER INC
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 724610859
Principal investigator 1 TARO PHARMACEUTICALS USA, INC. $468.00 03/20/2020 Non-covered Recipient Entity
L.A. Universal Research Center, Inc.
A Randomized, Double-Blind, Multiple Center Placebo Controlled Study Comparing Taro Product to RLD and Both Treatments to a Placebo Control in the Treatment of Acne Vulgaris No dispute reported 06/30/2026 721485521
Principal investigator 1 Bausch Health US, LLC $14,619.00 03/19/2020 Non-covered Recipient Individual A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2 ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-120 GEL AND IDP-120 VEHICLE GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737373813
Principal investigator 1 Bausch Health US, LLC $12,959.00 03/19/2020 Non-covered Recipient Individual A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2 ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-120 GEL AND IDP-120 VEHICLE GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737373815
Principal investigator 1 Sun Pharmaceutical Industries Inc. $9,360.90 03/18/2020 Non-covered Recipient Entity
LA UNIVERSAL RESEARCH CENTER INC
A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp No dispute reported 06/30/2026 726713243
Principal investigator 1 Sun Pharmaceutical Industries Inc. $8,316.00 03/10/2020 Non-covered Recipient Entity
LA UNIVERSAL RESEARCH CENTER INC
A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp No dispute reported 06/30/2026 726713247
Principal investigator 1 Sun Pharmaceutical Industries Inc. $4,558.50 03/05/2020 Non-covered Recipient Entity
LA UNIVERSAL RESEARCH CENTER INC
A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp No dispute reported 06/30/2026 726713251
Principal investigator 1 TARO PHARMACEUTICALS USA, INC. $2,763.00 02/20/2020 Non-covered Recipient Entity
L.A. Universal Research Center, Inc.
A Randomized, Double-Blind, Multiple Center Placebo Controlled Study Comparing Taro Product to RLD and Both Treatments to a Placebo Control in the Treatment of Acne Vulgaris No dispute reported 06/30/2026 721485517
Principal investigator 1 Bausch Health US, LLC $38,883.00 02/13/2020 Non-covered Recipient Individual A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2 ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-120 GEL AND IDP-120 VEHICLE GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737373333
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $383,772.84 02/11/2020 Non-covered Recipient Entity
La Universal Research Center
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Mod No dispute reported 06/30/2026 736760515
Principal investigator 1 TARO PHARMACEUTICALS USA, INC. $17,982.00 01/20/2020 Non-covered Recipient Entity
L.A. Universal Research Center, Inc.
A Randomized, Double-Blind, Multiple Center Placebo Controlled Study Comparing Taro Product to RLD and Both Treatments to a Placebo Control in the Treatment of Acne Vulgaris No dispute reported 06/30/2026 721485513
Principal investigator 1 Sun Pharmaceutical Industries Inc. $17,880.30 01/07/2020 Non-covered Recipient Entity
LA UNIVERSAL RESEARCH CENTER INC
A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp No dispute reported 06/30/2026 726713257